Article
Safety, pharmacokinetics and pharmacodynamics of the oral toll-like receptor 7 agonist GS-9620 in treatment-naive patients with chronic hepatitis C.
Antiviral therapy - 1 Jan 2015
Lawitz Eric, Gruener Daniel, Marbury Thomas, Hill John, Webster Lynn, Hassman David, Nguyen Anh-Hoa, Pflanz Stefan, Mogalian Erik, Gaggar Anuj, Massetto Benedetta, Subramanian G Mani, McHutchison John G, Jacobson Ira M, Freilich Bradley, Rodriguez-Torres Maribel
Abstract excerpt
BACKGROUND: GS-9620 is a potent oral agonist of toll-like receptor 7, a key modulator of the innate immune response. In healthy volunteers, low doses of GS-9620 (2, 4 and 6 mg) induced significant expression of peripheral interferon-stimulated-gene (ISG) mRNA in the absence of detectable serum interferon-α and systemic adverse events (AEs). We evaluated the safety, pharmacokinetics and pharmacodynamics of GS-9620...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.